SAN DIEGO, CA, United States
SAN DIEGO, CA, United States

Time filter

Source Type

Karoopongse E.,Fred Hutchinson Cancer Research Center | Marcondes A.M.,Fred Hutchinson Cancer Research Center | Marcondes A.M.,University of Washington | Yeung C.,University of Washington | And 5 more authors.
Biology of Blood and Marrow Transplantation | Year: 2016

Iron overload is common in patients undergoing hematopoietic cell transplantation (HCT). Peritransplant events, such as total body irradiation (TBI), and the effects of donor cell infusion may contribute to iron overload, in addition to disease-associated anemia and RBC transfusions. Using murine models we show complex time- and dose-dependent interactions of TBI and transplanted donor cells with expression patterns of iron regulatory genes in the liver. Infusion of allogeneic or syngeneic donor T lymphocytes increased serum iron, transiently up-regulated interleukin-6 (IL-6) and hepcidin (Hamp), and down-regulated ferroportin1 (Fpn1). After 7 to 14 days, however, changes were significant only with allogeneic cells. TBI (200 to 400 Gy) also induced IL-6 and Hamp expression but had little effect on Fpn1. TBI combined with allogeneic donor cell infusion resulted in modest early up-regulation of IL-6, followed by a decline in IL-6 levels and Hamp as well as Fpn1, and was accompanied by increased liver iron content. Injection of Fas ligand-deficient T lymphocytes from gld mice resulted in substantially lower alterations of gene expression than infusion of wild-type T cells. The agonistic anti-Fas antibody, JO2, triggered early up-regulation of Stat3 and IL-6, followed by an increase in Hamp and decreased expression of Fpn1 by 7 to 14 days, implicating Fas as a key modulator of gene expression in HCT. Minimal histologic changes were observed in mouse liver and duodenum. These data show profound and interacting effects of TBI and cell transplantation on the expression of iron regulatory genes in murine recipients. Alterations are largely related to induction of cytokines and Fas-dependent signals. © 2016 American Society for Blood and Marrow Transplantation.


Pierce R.H.,Oncosec Medical, Inc. | Campbell J.S.,Oncosec Medical, Inc. | Pai S.I.,Harvard University | Brody J.D.,Mount Sinai School of Medicine | Kohrt H.E.K.,Stanford University
Human Vaccines and Immunotherapeutics | Year: 2015

After decades of development in the shadow of traditional cancer treatment, immunotherapy has come into the spotlight. Treatment of metastatic tumors with monoclonal antibodies to T cell checkpoints like programed cell death 1 (PD-1) or its ligand, (PD-L1), have resulted in significant clinical responses across multiple tumor types. However, these therapies fail in the majority of patients with solid tumors, in particular those who lack PD1+CD8+ tumor-infiltrating lymphocytes within their tumors. Intratumoral “in situvaccination” approaches seek to enhance immunogenicity, generate tumor infiltrating lymophcytes (TIL) and drive a systemic anti-tumor immune response, directed against “unvaccinated,” disseminated tumors. Given the emerging picture of intratumoral immunotherapy as safe and capable of delivering systemic efficacy, it is anticipated that these approaches will become integrated into future multi-modality therapy. © 2015 Taylor & Francis Group, LLC.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 162.70K | Year: 2014

DESCRIPTION (provided by applicant): Here we seek to develop a more effective and targeted electroporation device for the clinical treatment of cancerous solid tumors. The application of using electroporation to transfect therapeutic agents into a tumor cells in the clinician setting is an exciting approach to a targeted treatment of cancer. The challenge for this work is to further develop a clinical electroporation device that will use the phenomenon of wave interference to produce a targeted electroporation waveform to increase the effectiveness of transfection. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: OncoSec Medical Incorporated is a small biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treatlocal solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize the detrimental effects resultin


PubMed | Oncosec Medical, Inc.
Type: Journal Article | Journal: Human vaccines & immunotherapeutics | Year: 2015

After decades of development in the shadow of traditional cancer treatment, immunotherapy has come into the spotlight. Treatment of metastatic tumors with monoclonal antibodies to T cell checkpoints like programed cell death 1 (PD-1) or its ligand, (PD-L1), have resulted in significant clinical responses across multiple tumor types. However, these therapies fail in the majority of patients with solid tumors, in particular those who lack PD1(+)CD8(+) tumor-infiltrating lymphocytes within their tumors. Intratumoral in situ vaccination approaches seek to enhance immunogenicity, generate tumor infiltrating lymophcytes (TIL) and drive a systemic anti-tumor immune response, directed against unvaccinated, disseminated tumors. Given the emerging picture of intratumoral immunotherapy as safe and capable of delivering systemic efficacy, it is anticipated that these approaches will become integrated into future multi-modality therapy.


Oncosec Medical, Inc. | Entity website

Intratumoral Immunization: A New Paradigm for Cancer Therapy Marabell et al. This French group, in collaboration with Dr ...


Oncosec Medical, Inc. | Entity website

Click on the month to show all Press Releases


News Article | July 5, 2011
Site: www.xconomy.com

San Diego’s OncoSec Medical, which trades on the over-the-counter bulletin board as ONCSD, recently raised $3 million through a private stock placement with rights to acquire additional securities at set prices, according to a regulatory filing. In a statement last week, the company says the deal includes a series of warrants that enables the buyer to purchase additional shares of the company’s common stock at either 75 cents a share or $1.20 a share. Founded in 2008, OncoSec has been developing a proprietary electroporation delivery technology that is intended to make cancer cells more vulnerable to chemotherapeutic or novel DNA-based immunotherapeutics.


SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced it will provide a comprehensive corporate update and Q&A session for investors and the general public during a webinar starting at 9:30 AM PDT on Monday, March 23, 2015. Punit Dhillon, President and CEO, will host the webinar to provide an engaging, educational discussion regarding the company and its outlook for the upcoming year. Attendees will hear first-hand from the CEO as he shares updates on several pertinent topics, including: clinical trials timeline, research activities, development of new electroporation devices, financial updates, and current market opportunity in the cancer immunotherapy landscape. The company will also address questions from the public during the webinar’s Q&A session. OncoSec encourages people to submit their questions prior to the webinar via OncoSec’s social media channels: Twitter (https://twitter.com/oncosec) and Facebook (https://www.facebook.com/oncosecmedical). To register for the event, please click on the following link at any time prior to the webinar: https://attendee.gotowebinar.com/register/4040606641159991809. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. After registering, you will receive a confirmation email containing information about joining the webinar. For technical assistance, please contact Go To Webinar at 855-352-9002. For those unable to attend to the live webinar, an archive version will be available for 90 days on OncoSec’s website: http://www.oncosec.com. OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec’s core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec’s lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at Needham & Company’s 14th Annual Healthcare Conference on Tuesday, April 14, 2015 in New York City. The presentation is scheduled to begin at 8:40 AM ET at the Westin Grand Central Hotel. Each year, Needham’s Healthcare Conference features presentations from approximately 100 companies in the biotechnology, specialty pharmaceutical, medical technology and diagnostic sectors. The conference focuses on connecting leading public and private life science companies and investors. One-on-one meetings with companies will be available for qualified institutional investors and venture capital firms. For more information, please visit: http://www.needhamco.com. OncoSec invites investors and the general public to view and listen to the live webcast. At the time of the presentation, the webcast will be available via the following link: http://wsw.com/webcast/needham71/oncs. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. After the presentation, an archived version of the webcast will be available for 90 days on OncoSec’s website: http://www.oncosec.com. OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec’s core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Loading Oncosec Medical, Inc. collaborators
Loading Oncosec Medical, Inc. collaborators